Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Return on Sales (2021 - 2025)

Kiniksa Pharmaceuticals International's Return on Sales history spans 5 years, with the latest figure at 0.36% for Q4 2025.

  • For Q4 2025, Return on Sales fell 58.0% year-over-year to 0.36%; the TTM value through Dec 2025 reached 0.04%, down 2.0%, while the annual FY2025 figure was 0.04%, 2.0% down from the prior year.
  • Return on Sales reached 0.36% in Q4 2025 per KNSA's latest filing, down from 0.1% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 6.83% in Q4 2021 to a low of 5.39% in Q2 2021.
  • Average Return on Sales over 5 years is 0.06%, with a median of 0.04% recorded in 2024.
  • The largest YoY upside for Return on Sales was 479bps in 2022 against a maximum downside of -617bps in 2022.
  • A 5-year view of Return on Sales shows it stood at 6.83% in 2021, then plummeted by -90bps to 0.65% in 2022, then surged by 113bps to 1.4% in 2023, then plummeted by -84bps to 0.23% in 2024, then plummeted by -257bps to 0.36% in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Return on Sales are 0.36% (Q4 2025), 0.1% (Q3 2025), and 0.11% (Q2 2025).